-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with behavioral variants of Alzheimer's disease (bvAD) experience significant early behavioral symptoms and personality changes, such as disinhibition, compulsive behavior, and loss of empathy.
The purpose of this study is to study the uneven distribution of tau in bvAD.
In the PET study, 7 amyloid beta-positive bvAD patients underwent PET examination.
The pathological distribution of tau in the brains of Alzheimer's disease behavior variants (bvAD, shown separately) and Alzheimer's disease subjects (tAD, shown as the average of the group).
Immunohistochemical study of tau in patients with bvAD and AD after death
immunityIn the tau-PET study, 6/7 (85.
Whether in vivo or in vitro, the pathological distribution of tau in bvAD patients is uneven.
Whether in vivo or in vitro, the pathological distribution of tau in bvAD patients is uneven.
Since the key areas involved in behavior regulation are not always disproportionately affected by tau pathology, other factors are more likely to lead to the clinical phenotype of bvAD.
SingletonE ,HanssonO ,PijnenburgYAL SingletonE Singleton HanssonO Hansson PijnenburgYAL Pijnenburg , et al bmj.
com/content/early/2021/04/12/jnnp-2020-325497" target="_blank" rel="noopener">Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease Journal of Neurology, Neurosurgery & PsychiatryPublished Online First:13 April 2021.
Published Online First : doi:10.
1136/jnnp-2020-325497 doi: leave a message here
